At a glance
ClinicalIndex Comparison RecordN/ACompleted· 300 enrolled
Drug / intervention
Valchlordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®
In Brief
An observational study evaluating Valchlor for Mycosis Fungoides. Completed, enrolled 300 participants across 36 sites.
Detailed Summary
The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 2 years from the date of signed informed consent (enrollment) until end of study. Continuation in the study is not contingent on continuation of Valchlor.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMycosis Fungoides
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedNov 2014
Primary CompletionOct 2018
TodayJul 2026
First PostedNov 20, 2014
Enrollment StartNov 12, 2014
Primary CompletionOct 17, 2018
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.6 years ago
Interventions
Valchlordrug
Valchlor gel 0.016%